ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ 9¿ù Á¤±âÁý´ãȸ : 2018-09-04±³À°ÀÏÀÚ : 2018-09-04
±³À°Àå¼Ò : ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë
±³À°ÁÖÁ¦ :
ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ 9¿ù Á¤±âÁý´ãȸ ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï»ê°æ³²Áöȸ
´ã´çÀÚ : ±è»óÈñ
¿¬¶ôó : 051-990-6671
À̸ÞÀÏ :
sh1215793@naver.com ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 04ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë 19:00~19:50 Energy Balance and Metabolic changes with SGLT-2i John Wilding(Liverpool School of Medicine)
±³À°½Ã°£ 09¿ù 04ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ41Ãþ »çÆÄÀ̾î·ë 19:50~21:10 Treatment of hypertension in patients with metabolic syndrome and T2DM ±è¼±¿ì(Çѱ¹´ÙÄÉ´Ù)
±³À°½Ã°£ 09¿ù 04ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ41Ãþ »çÆÄÀ̾î·ë 21:10~22:00 Post ADA - Mechanistic and Therapeuitc Rationale for Dual SGLT1/2 lnhibition in Adults with Type 1 Diabetes ³²±ÃÀϼº(¿ï»êÀÇ´ë)